News
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
NEW YORK, NY, USA I June 26, 2025 I Pfizer Inc. (NYSE: PFE)today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating ...
SAN FRANCISCO, CA, USA and SUZHOU, China I June 27, 2025 I Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical ...
SEATTLE, WA, USA I June 27, 2025 I Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to ...
Initiation follows successful IND clearance based on preclinical data package indicating robust increase in fetal hemoglobin with no cytotoxicity ...
SHANGHAI, China I June 27, 2025 I Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned ...
ATLANTA, GA, USA I June 27, 2025 I UCB, a global biopharmaceutical company, today announced that the Phase 3 study investigating the safety and efficacy of ...
TOKYO, Japan I June 27, 2025 I PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting ...
LEIDEN, The Netherlands & CAMBRIDGE, MA, USA I June 26, 2025 I ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through ...
STUTTGART, Germany I June 27, 2025 I La Merie Publishing announced the release of its newest technology market report about gene therapy technologies for in vivo expression of antibodies. The report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results